Q2 FY26: Standalone PAT down 23%, Consolidated PAT up 71%
HESTERBIO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.4 pts more than Nifty Microcap 250 and 2.6 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Q2 FY26 results: Standalone sales fell 12% to INR 645.79M, PAT down 23% to INR 72.09M as Animal Healthcare division dropped 50% on delayed government immunisation programmes. Poultry Healthcare grew 18%. Consolidated PAT jumped 71% to INR 143.31M and H1 FY26 consolidated PAT nearly doubled to INR 316.27M, driven by Hester Africa profitability and forex. H9N2 vaccine got market authorisation.
Mixed results - standalone weak on government order delays, but consolidated strong on Hester Africa. Recovery in H2 hinges on resumption of institutional orders.